Thu, February 5, 2009
Wed, February 4, 2009
Tue, February 3, 2009
Mon, February 2, 2009
Sun, February 1, 2009
Sat, January 31, 2009
Fri, January 30, 2009
[ Fri, Jan 30th 2009 ]: Market Wire
Progen-Avexa Merger Update
Thu, January 29, 2009
Wed, January 28, 2009
Tue, January 27, 2009
[ Tue, Jan 27th 2009 ]: Market Wire
SCOR: SCOR sets up Zurich Hub
Mon, January 26, 2009
Sun, January 25, 2009
Fri, January 23, 2009
Thu, January 22, 2009
Wed, January 21, 2009

XenoPort to Release Fourth Quarter Financial Results on February 12, 2009


  Copy link into your clipboard //health-fitness.news-articles.net/content/2009/ .. arter-financial-results-on-february-12-2009.html
  Print publication without navigation Published in Health and Fitness on , Last Modified on 2009-01-29 11:06:00 by Market Wire


SANTA CLARA, Calif.--([ BUSINESS WIRE ])--XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its fourth quarter and fiscal year end financial results on February 12, 2009 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.

To access the conference call via the Internet, go to [ www.XenoPort.com ]. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.

To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 83488800.

The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at [ www.XenoPort.com ], or via phone at 1-800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reference number to enter the replay of the call is 83488800.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in partnership with Astellas Pharma Inc. and GlaxoSmithKline. XenoPort's product candidates are being studied for the potential treatment of restless legs syndrome, neuropathic pain, migraine headaches, gastroesophageal reflux disease, spasticity related to spinal cord injury, acute back spasms and Parkinson's disease.

To learn more about XenoPort, please visit the Web site at [ www.XenoPort.com ].

XenoPort is a registered trademark.

XNPT2F


Publication Contributing Sources